Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

NCT01409161 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

151

Enrollment

OTHER

Sponsor class

Conditions

Acute Promyelocytic Leukemia With PML-RARA

Interventions

DRUG: Arsenic Trioxide
DRUG: Gemtuzumab Ozogamicin
OTHER: Laboratory Biomarker Analysis
DRUG: Tretinoin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]